Intellectual Property Rights and Responsibilities

The EDRN is premised on the belief that an established integrated, multi-disciplinary environment will expedite clinical applications of biomarker research. NCI anticipates that EDRN members will collaborate with industry both to develop biomarkers and/or reagents and to provide a clinical environment for the evaluation of new technologies. Early interactions with industry are expected to permit research collaborations likely to benefit both EDRN grantees and industry partners. It is hoped that validated biomarkers may ultimately be commercialized into diagnostic products for early detection of cancer and cancer risk. Many EDRN investigators have had active collaborations with industry. Restricted availability of unique research resources, upon which further studies are dependent, can impede the advancement of research. The NIH is interested in ensuring that the research resources developed through its grants also become readily available to the broader research community in a timely manner for further research, development, and application, with the expectation that this will lead to products and knowledge of benefit to the public health.
Version 5.1.0